 recombin granulocyte-macrophag colony-stimul factor autolog bone marrow transplant lymphoid cancer background period neutropenia autolog bone marrow transplant result substanti morbid mortal result previou phase i-ii clinic trial recombin human granulocyte-macrophag colony-stimul factor rhgm-csf neutrophil recoveri complic patient autolog bone marrow transplant method double-blind placebo-control trial institut studi design treatment schedul ident result analysi twenty-eight patient sixty-f patient rhgm-csf two-hour intraven infus day hour marrow infus patient result No toxic effect patient rhgm-csf recoveri neutrophil count liter day patient placebo day infect day antibiot administr day day initi hospit median day differ surviv rate day conclus patient autolog bone marrow transplant lymphoid neoplasia rhgm-csf morbid further studi optim dosag schedul administr